In contrast, pre-treatment with NFκB inhibitor BAY 11–7082 abrogated LPS-induced IL-6 production in 4T1-conditioned BMDMs, suggesting a role for the NFκB pathway in the tumor-conditioning of BMDMs. Here, NFKB1 is linked to neoplasm.